Casdin Capital, LLC
Filing Date
Global Rank
#1,592
/ 8,794
▲ 194
· as of Jun 2026
Top Industry
Biotechnology
63.0%
Period ended 3 months ago
Filed Aug 14, 2026 · 51d
26 quarters · since Mar 2020
Clone Performance
Build a hypothetical price-return history from this filer's public 13F holdings.
View clone backtestPortfolio Concentration
43 tracked positions · as of Jun 30, 2026 · Δ vs Mar 31, 2026Top Position
24.2%
+5.2 pts
Top 5
63.2%
+3.9 pts
Top 10
77.4%
+0.1 pts
HHI
1,105
Diversified+202
Portfolio Trend
26 quarters · across all stocks
Sector Breakdown
As of Jun 30, 2026| Sector | % Portfolio | Value |
|---|---|---|
| Healthcare | 100.0% | $1,997,559,234 |
Last Quarter's Activity
Export CSVAdded To
Positions the filer increased
9 positions
| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| RLAY | Relay Therapeutics, Inc. | +1,616,666 | 16,035,240 | $300,019,340 | |
| PSNL | Personalis, Inc. | +950,000 | 2,550,000 | $34,170,000 | |
| ANL | Adlai Nortye Group Ltd. | +711,539 | 1,250,000 | $14,375,000 | |
| WGS | GeneDx Holdings Corp. | +700,000 | 3,707,164 | $254,496,808 | |
| SRRK | Scholar Rock Holding Corp | +315,000 | 665,000 | $36,575,000 | |
| GRAL | GRAIL, Inc. | +250,000 | 480,000 | $32,769,600 | |
| DNLI | Denali Therapeutics Inc. | +205,000 | 2,045,000 | $52,597,400 | |
| NGNE | Neurogene Inc. | +125,000 | 1,545,361 | $48,601,603 | |
| MAZE | Maze Therapeutics, Inc. | +85,000 | 843,857 | $25,180,692 | |
| No positions match the current search. | |||||
New Positions
Positions the filer opened this quarter
6 positions
| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| PBLS | Parabilis Medicines, Inc. | 645,690 | $17,672,535 | |
| SION | Sionna Therapeutics, Inc. | 400,000 | $17,596,000 | |
| SRPT | Sarepta Therapeutics, Inc. | 470,000 | $8,445,900 | |
| QURE | uniQure N.V. | 150,000 | $6,909,000 | |
| EDIT | Editas Medicine, Inc. | 445,000 | $1,441,800 | |
| KARD | Kardigan, Inc. | 50,000 | $1,192,500 | |
| No positions match the current search. | ||||
43 tracked positions ·
$1,997,559,234 total
· filing declares
43 positions · $1,997,798,996
· as of Jun 30, 2026
| Ticker | Company | Type | Shares | Value (USD) | % of Portfolio | History |
|---|---|---|---|---|---|---|
| RVMD |
Revolution Medicines, Inc.
Healthcare
|
Held | 2,577,333 | $482,682,924 | 24.16% | |
| RLAY |
Relay Therapeutics, Inc.
Healthcare
|
Added | 16,035,240 | $300,019,340 | 15.02% | |
| WGS |
GeneDx Holdings Corp.
Healthcare
|
Added | 3,707,164 | $254,496,808 | 12.74% | |
| BLFS |
Biolife Solutions Inc
Healthcare
|
Reduced | 4,655,000 | $131,457,200 | 6.58% | |
| ILMN |
Illumina, Inc.
Healthcare
|
Held | 530,000 | $93,189,900 | 4.67% | |
| LAB |
Standard Biotools Inc.
Healthcare
|
Held | 88,783,856 | $72,802,761 | 3.64% | |
| GPCR |
Structure Therapeutics Inc.
Healthcare
|
Held | 1,175,000 | $63,062,250 | 3.16% | |
| DNLI |
Denali Therapeutics Inc.
Healthcare
|
Added | 2,045,000 | $52,597,400 | 2.63% | |
| NGNE |
Neurogene Inc.
Healthcare
|
Added | 1,545,361 | $48,601,603 | 2.43% | |
| BEAM |
Beam Therapeutics Inc.
Healthcare
|
Held | 1,350,000 | $46,332,000 | 2.32% | |
| TXG |
10x Genomics, Inc.
Healthcare
|
Reduced | 1,050,000 | $40,257,000 | 2.02% | |
| SRRK |
Scholar Rock Holding Corp
Healthcare
|
Added | 665,000 | $36,575,000 | 1.83% | |
| PSNL |
Personalis, Inc.
Healthcare
|
Added | 2,550,000 | $34,170,000 | 1.71% | |
| GRAL |
GRAIL, Inc.
Healthcare
|
Added | 480,000 | $32,769,600 | 1.64% | |
| GH |
Guardant Health, Inc.
Healthcare
|
Reduced | 185,000 | $27,755,550 | 1.39% | |
| MAZE |
Maze Therapeutics, Inc.
Healthcare
|
Added | 843,857 | $25,180,692 | 1.26% | |
| HIMS |
Hims & Hers Health, Inc.
Healthcare
|
Held | 700,000 | $24,269,000 | 1.21% | |
| ALNY |
Alnylam Pharmaceuticals, Inc.
Healthcare
|
Held | 75,000 | $22,577,250 | 1.13% | |
| TSHA |
Taysha Gene Therapies, Inc.
Healthcare
|
Held | 3,250,000 | $22,132,500 | 1.11% | |
| AGMB |
AgomAb Therapeutics NV
Healthcare
|
Held | 1,550,000 | $20,119,000 | 1.01% | |
| SEPN |
Septerna, Inc.
Healthcare
|
Held | 553,268 | $18,528,945 | 0.93% | |
| PBLS |
Parabilis Medicines, Inc.
Healthcare
|
NEW | 645,690 | $17,672,535 | 0.88% | |
| SION |
Sionna Therapeutics, Inc.
Healthcare
|
NEW | 400,000 | $17,596,000 | 0.88% | |
| VCYT |
Veracyte, Inc.
Healthcare
|
Held | 276,308 | $16,227,568 | 0.81% | |
| ANL |
Adlai Nortye Group Ltd.
Healthcare
|
Added | 1,250,000 | $14,375,000 | 0.72% | |
| PRME |
Prime Medicine, Inc.
Healthcare
|
Held | 3,167,175 | $11,686,875 | 0.59% | |
| ABSI |
Absci Corp
Healthcare
|
Held | 973,260 | $11,280,083 | 0.56% | |
| DGX |
Quest Diagnostics Inc
Healthcare
|
Held | 50,000 | $10,597,500 | 0.53% | |
| SRPT |
Sarepta Therapeutics, Inc.
Healthcare
|
NEW | 470,000 | $8,445,900 | 0.42% | |
| QURE |
uniQure N.V.
Healthcare
|
NEW | 150,000 | $6,909,000 | 0.35% | |
| NTLA |
Intellia Therapeutics, Inc.
Healthcare
|
Held | 355,000 | $6,006,600 | 0.30% | |
| MRNA |
Moderna, Inc.
Healthcare
|
Held | 75,000 | $5,252,250 | 0.26% | |
| IRON |
Disc Medicine, Inc.
Healthcare
|
Held | 65,000 | $4,754,100 | 0.24% | |
| GLUE |
Monte Rosa Therapeutics, Inc.
Healthcare
|
Held | 186,014 | $4,501,538 | 0.23% | |
| IPSC |
Century Therapeutics, Inc.
Healthcare
|
Held | 1,228,190 | $3,009,065 | 0.15% | |
| CTNM |
Contineum Therapeutics, Inc.
Healthcare
|
Held | 148,333 | $2,431,177 | 0.12% | |
| BBOT |
BridgeBio Oncology Therapeutics, Inc.
Healthcare
|
Held | 282,312 | $2,151,217 | 0.11% | |
| EDIT |
Editas Medicine, Inc.
Healthcare
|
NEW | 445,000 | $1,441,800 | 0.07% | |
| PACB |
Pacific Biosciences Of California, Inc.
Healthcare
|
Held | 723,767 | $1,215,928 | 0.06% | |
| KARD |
Kardigan, Inc.
Healthcare
|
NEW | 50,000 | $1,192,500 | 0.06% | |
| RXRX |
Recursion Pharmaceuticals, Inc.
Healthcare
|
Held | 165,323 | $606,735 | 0.03% | |
| DNA |
Ginkgo Bioworks Holdings, Inc.
Healthcare
|
Held | 36,493 | $361,645 | 0.02% | |
| TNYA |
Tenaya Therapeutics, Inc.
Healthcare
|
Held | 361,969 | $267,495 | 0.01% |
Covers the securities this platform tracks: U.S.-listed common stock and the put/call positions reported on it. A 13F can also report security types outside that coverage — preferred shares, bonds, warrants, untracked share classes — so the filing's own declared total can exceed the figures above. The source filing is linked at the top of this table.